News

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, months before they were abruptly fired by U.S. Health Secretary Robert F ...
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
With the CDC director's chair still empty, HHS Secretary Robert F. Kennedy Jr. endorsed recommendations made months ago by ...
Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...
The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...
Key Takeaways High-risk adults as young as 50 are now eligible for the RSV vaccineThe update follows advice from now-deposed ...
GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...
The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...